Hikma Pharmaceuticals (LON:HIK - Get Free Report)'s stock had its "equal weight" rating reaffirmed by investment analysts at Barclays in a research note issued to investors on Monday, Marketbeat Ratings reports. They presently have a GBX 2,000 ($25.31) price target on the stock. Barclays's price objective would indicate a potential upside of 8.75% from the stock's current price.
Separately, Berenberg Bank increased their price target on Hikma Pharmaceuticals from GBX 1,960 ($24.81) to GBX 2,000 ($25.31) and gave the company a "hold" rating in a research report on Monday, February 26th. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, Hikma Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus price target of GBX 2,068.75 ($26.18).
Read Our Latest Stock Analysis on HIK
Hikma Pharmaceuticals Trading Down 1.3 %
Shares of Hikma Pharmaceuticals stock traded down GBX 24 ($0.30) during trading hours on Monday, hitting GBX 1,839 ($23.28). The company's stock had a trading volume of 182,316 shares, compared to its average volume of 437,089. Hikma Pharmaceuticals has a 12 month low of GBX 1,711 ($21.66) and a 12 month high of GBX 2,222 ($28.12). The stock has a 50 day moving average of GBX 1,923.57 and a 200 day moving average of GBX 1,894.59. The company has a market capitalization of £4.08 billion, a PE ratio of 2,744.78, a price-to-earnings-growth ratio of 2.38 and a beta of 0.45. The company has a debt-to-equity ratio of 53.92, a current ratio of 1.57 and a quick ratio of 1.27.
About Hikma Pharmaceuticals
(
Get Free Report)
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms in North America, the Middle East, North Africa, and Europe. It operates through three segments: Injectables, Generics, and Branded.
Further Reading
Before you consider Hikma Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hikma Pharmaceuticals wasn't on the list.
While Hikma Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?
Get This Free Report
